Showing 971-980 of 1780 results for "".
- Study Reveals TikTok's Impact on Psoriasis Treatment Understandinghttps://practicaldermatology.com/news/study-reveals-tiktoks-impact-on-psoriasis-treatment-understanding/2462223/A new study published in the Journal of Drugs in Dermatology offers a glimp
- Guselkumab Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Colorhttps://practicaldermatology.com/news/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-3b-study/2462218/At the Maui Derm Hawaii 2024 conference, Johnson & Johnson presented topline data from Cohort B in the Phase 3b VISIBLE study that demonstrated that TREMFYA® (guselkumab) showed rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement
- Upadacitinib in Atopic Dermatitis: New Safety Data Encourages Practitioners and Patientshttps://practicaldermatology.com/news/long-term-safety-of-upadacitinib-in-atopic-dermatitis-5-year-analysis-unveils-encouraging-results/2462210/A recent analysis reveals that upadacitinib, an oral Janus kinase 1 (JAK1) inhibitor, maintains its safety profile over a span of 5 years, aiding individuals
- Melanoma Rates Among Non-Hispanic American Indian/Alaska Natives Vary by Age, Region: Studyhttps://practicaldermatology.com/news/melanoma-rates-among-non-hispanic-american-indianalaska-native-individuals/2462199/A new study in JAMA Dermatology shed light on trends and incidence rates of invasive cutaneous melanoma in non-Hispanic American Indian/Alaska Native individuals. The cross-sectional observational study, focusing on a period from 1999 to 2019, included data drawn from a populati
- Venous Thromboembolism Risk Lower in AD Patients: Analysishttps://practicaldermatology.com/news/venous-thromboembolism-risk-lower-in-ad-patients-analysis/2462196/A retrospective, observational analysis in the Journal of the American Academy of Dermatology showed that patients with atopic dermatitis (AD) do not have an increased risk for venous thromboembolism (VTE) compared with other immune-mediated inflammatory diseases. The ana
- Birch Triterpenes Topical Gel Gets FDA Approval for Treatment of Epidermolysis Bullosahttps://practicaldermatology.com/news/birch-triterpenes-topical-gel-gets-fda-approval-for-treatment-of-epidermolysis-bullosa/2462190/Chiesi Global Rare Diseases announced today that the FDA had approved FILSUVEZ® (birch triterpenes) topical gel for the treatment of junctional epidermolysis bullosa (JEB) and dystrophic epidermolysis bullosa (DEB) in patients 6 months or older. According
- Study: Individuals With Acne Face Social and Professional Stigmahttps://practicaldermatology.com/news/study-individuals-with-acne-face-social-and-professional-stigma/2462175/Individuals with acne face social and professional stigma, and people with darker skin tones and more severe acne are disproportionately more likely to face greater stigma. These results, published in JAMA Dermatology, highlight the need to identify ways to
- AI in Action: Almirall, Barcelona Supercomputing Center, and Nostrum Biodiscovery Seek New Dermatologic Therapies via AIhttps://practicaldermatology.com/news/ai-in-action-almirall-barcelona-supercomputing-center-bsc-and-nostrum-biodiscovery-seek-new-dermatologic-therapies-via-ai/2462171/Almirall S.A. (BME: ALM), Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS) and Nostrum Biodiscovery are joining forces to explore artificial intelligence (AI) and machine learning (ML) generative approaches to design new protein-protein modulators for dermatolo
- DermWire’s AD Pipeline Watch: TDM 180935 Performs Well in Phase 1 Studyhttps://practicaldermatology.com/news/dermwires-ad-pipeline-watch-tdm-180935-performs-well-in-phase-1-study/2462168/Technoderma Medicines, Inc. has completed a Phase 1 clinical trial of TDM-180935 topical ointment for Atopic Dermatitis (AD). TDM 180935 is a small molecule drug candidate that functions as a potent JAK1/Tyk2 small molecule inhibitor. Preclinical assessment of TDM-180935 has demon
- Biosimilar News: Samsung Bioepis Secures US License Date for Proposed Stelara Biosimilarhttps://practicaldermatology.com/news/biosimilar-news-samsung-bioepis-secures-us-license-date-for-proposed-stelara-biosimilar/2462165/Samsung Bioepis Co., Ltd. signed a settlement and license agreement with Johnson & Johnson settling all pending US patent litigation between the two companies and clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of reference medicine Stelara&nb